Late cardiac effects of cancer treatment

Journal of Clinical Oncology

Volumn 30, Issue 30, 2012, Pages 3657-3664

  Lenihan, Daniel J ^a   Cardinale, Daniela M ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE DERIVATIVE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARVEDILOL; CISPLATIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; EPIRUBICIN; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; MITOXANTRONE; PAZOPANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; THROMBIN INHIBITOR; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; WARFARIN;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ATHEROSCLEROSIS; BRADYCARDIA; BREAST CANCER; CANCER SURVIVOR; CANCER THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CAROTID ARTERY STENTING; CAROTID ATHEROSCLEROSIS; CONSTRICTIVE PERICARDITIS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; EARLY DIAGNOSIS; EDEMA; ELECTROLYTE DISTURBANCE; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART DISEASE; HEART FAILURE; HEART VALVE STENOSIS; HODGKIN DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LUNG NODULE; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; PHARMACOGENOMICS; PRIORITY JOURNAL; RADIATION SICKNESS; REVIEW; RISK ASSESSMENT; SARCOMA; SCREENING; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC DYSFUNCTION; THERAPY EFFECT; THROMBOSIS; THROMBOSIS PREVENTION; VALVULAR HEART DISEASE;

ADULT; CARDIOMYOPATHIES; FEMALE; HEART DISEASES; HEART FAILURE; HUMANS; MIDDLE AGED; NEOPLASMS; SURVIVORS; YOUNG ADULT;

EID: 84869098325     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.2938     Document Type: Review

References (92)

1. Yeh ET, Tong AT, Lenihan DJ, et al: Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 109:3122-3131, 2004
2. Carver JR, Shapiro CL, Ng A, et al: American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. J Clin Oncol 25:3991-4008, 2007 (Pubitemid 47477279)
3. Oeffinger KC, Mertens AC, Sklar CA, et al: Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572-1582, 2006 (Pubitemid 44547808)
4. Reulen RC, Winter DL, Frobisher C, et al: Long-term cause-specific mortality among survivors of childhood cancer. JAMA 304:172-179, 2010
5. Chen MH, Colan SD, Diller L: Cardiovascular disease: Cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res 108:619-628, 2011
6. Ng AK, LaCasce A, Travis LB: Long-term complications of lymphoma and its treatment. J Clin Oncol 29:1885-1892, 2011
7. Azim HA Jr, de Azambuja E, Colozza M, et al: Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol 22:1939-1947, 2011
8. Hequet O, Le QH, Moullet I, et al: Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22:1864-1871, 2004
9. van den Belt-Dusebout AW, Nuver J, de Wit R, et al: Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24:467-475, 2006
10. Haugnes HS, Wethal T, Aass N, et al: Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 28:4649-4657, 2010
11. Mertens AC, Liu Q, Neglia JP, et al: Cause-specific late mortality among 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 100:1368-1379, 2008
12. Heidenreich PA, Hancock SL, Lee BK, et al: Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42:743-749, 2003 (Pubitemid 37000197)
13. Khakoo AY, Kassiotis CM, Tannir N, et al: Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer 112:2500-2508, 2008
14. Hull MC, Morris CG, Pepine CJ, et al: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 290:2831-2837, 2003 (Pubitemid 37509491)
15. Giordano SH, Kuo YF, Freeman JL, et al: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97:419-424, 2005 (Pubitemid 40528604)
16. Vaklavas C, Lenihan D, Kurzrock R, et al: Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: What are the important clinical markers to target? Oncologist 15:130-141, 2010
17. Subbiah IM, Lenihan DJ, Tsimberidou AM: Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist 16:1120-1130, 2011
18. Adams MJ, Lipshultz SE, Schwartz C, et al: Radiation-associated cardiovascular disease: Manifestations and management. Semin Radiat Oncol 13:346-356, 2003 (Pubitemid 36962655)
19. Jarfelt M, Kujacic V, Holmgren D, et al: Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 49:835-840, 2007 (Pubitemid 47519523)
20. Ewer MS, Von Hoff DD, Benjamin RS: A historical perspective of anthracycline cardiotoxicity. Heart Fail Clin 7:363-372, 2011
21. Curigliano G, Mayer EL, Burstein HJ, et al: Cardiac toxicity from systemic cancer therapy: A comprehensive review. Prog Cardiovasc Dis 53:94-104, 2010
22. Steingart RM, Bakris GL, Chen HX, et al: Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J 163:156-163, 2012
23. Force T, Krause DS, Van Etten RA: Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332-344, 2007 (Pubitemid 46652481)
24. Correa CR, Litt HI, Hwang WT, et al: Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 25:3031-3037, 2007 (Pubitemid 47218049)
25. Heidenreich PA, Schnittger I, Strauss HW, et al: Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 25:43-49, 2007 (Pubitemid 350003049)
26. Witteles RM: Radiation therapy for breast cancer: Buyer beware. J Am Coll Cardiol 57:453-454, 2011
27. Zagar TM, Marks LB: Breast cancer radiotherapy and coronary artery stenosis: Location, location, location. J Clin Oncol 30:350-352, 2012
28. Nilsson G, Holmberg L, Garmo H, et al: Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol 30:380-386, 2012
29. Protack CD, Bakken AM, Saad WE, et al: Radiation arteritis: A contraindication to carotid stenting? J Vasc Surg 45:110-117, 2007 (Pubitemid 46038662)
30. Moritz MW, Higgins RF, Jacobs JR: Duplex imaging and incidence of carotid radiation injury after high-dose radiotherapy for tumors of the head and neck. Arch Surg 125:1181-1183, 1990 (Pubitemid 20283113)
31. Fakhouri F, La Batide Alanore A, Rérolle JP, et al: Presentation and revascularization outcomes in patients with radiation-induced renal artery stenosis. Am J Kidney Dis 38:302-309, 2001
32. Sanon S, Lenihan DJ, Mouhayar E: Peripheral arterial ischemic events in cancer patients. Vasc Med 16:119-130, 2011
33. Javid M, Magee TR, Galland RB: Arterial thrombosis associated with malignant disease. Eur J Vasc Endovasc Surg 35:84-87, 2008 (Pubitemid 350235237)
34. Jones LW, Haykowsky MJ, Swartz JJ, et al: Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 50:1435-1441, 2007 (Pubitemid 47494586)
35. Alfano CM, Ganz PA, Rowland JH, et al: Cancer survivorship and cancer rehabilitation: Revitalizing the link. J Clin Oncol 30:904-906, 2012
36. McCullough LE, Eng SM, Bradshaw PT, et al: Fat or fit: The joint effects of physical activity, weight gain, and body size on breast cancer risk. Cancer [epub ahead of print on June 25, 2012]
37. Maitland ML, Bakris GL, Black HR, et al: Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596-604, 2010
38. Cheng H, Force T: Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 106:21-34, 2010
39. Schutz FA, Je Y, Richards CJ, et al: Metaanalysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 30:871-877, 2012
40. Imperatori A, Mariscalco G, Riganti G, et al: Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study. J Cardiothorac Surg 7:4, 2012
41. Kuter DJ: Thrombotic complications of central venous catheters in cancer patients. Oncologist 9:207-216, 2004
42. Meyer G, Marjanovic Z, Valcke J, et al: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med 162:1729-1735, 2002
43. Lee AY, Levine MN, Baker RI, et al: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153, 2003 (Pubitemid 36818784)
44. Otten HM, Mathijssen J, ten Cate H, et al: Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: An underestimated phenomenon. Arch Intern Med 164:190-194, 2004 (Pubitemid 38140406)
45. Yusuf SW, Sarfaraz A, Durand JB, et al: Management and outcomes of severe aortic stenosis in cancer patients. Am Heart J 161:1125-1132, 2011
46. Maisch B, Ristic A, Pankuweit S: Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis 53: 157-163, 2010
47. Eckstein PF: Postirradiation pericardiectomy. Ann Thorac Surg 50:685, 1990
48. Ni Y, von Segesser LK, Turina M: Futility of pericardiectomy for postirradiation constrictive pericarditis? Ann Thorac Surg 49:445-448, 1990 (Pubitemid 20097041)
49. Galper SL, Yu JB, Mauch PM, et al: Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 117:412-418, 2011
50. van der Pal HJ, van Dalen EC, van Delden E, et al: High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 30:1429-1437, 2012
51. Felker GM, Thompson RE, Hare JM, et al: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077-1084, 2000 (Pubitemid 30207690)
52. Bird BR, Swain SM: Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems. Clin Cancer Res 14:14-24, 2008 (Pubitemid 351377973)
53. National Cancer Institute: Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, version 4.0, 2009. http://ctep.cancer. gov/protocolDevelopment/electronic-applications/ctc.htm
54. Lenihan DJ, Cardinale D, Cipolla CM: The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis 53:88-93, 2010
55. Lenihan DJ: Tyrosine kinase inhibitors: Can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork? J Clin Oncol 26:5154-5155, 2008
56. Lenihan DJ, Massey MR, Baysinger K, et al: Early detection of cardiotoxicity during chemotherapy using biomarkers. J Clin Oncol 25:708s, 2007 (suppl 18; abstr 19521)
57. Noori A, Lindenfeld J, Wolfel E, et al: Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail 6:115-119, 2000
58. Cardinale D, Colombo A, Lamantia G, et al: Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55:213-220, 2010
59. Cardinale D, Colombo A, Sandri MT, et al: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-2481, 2006 (Pubitemid 44901520)
60. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
61. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
62. Ewer MS, Vooletich MT, Durand JB, et al: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820-7826, 2005 (Pubitemid 46657379)
63. Telli ML, Hunt SA, Carlson RW, et al: Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 25:3525-3533, 2007 (Pubitemid 47310891)
64. Schmidinger M, Zielinski CC, Vogl UM, et al: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204-5212, 2008
65. Telli ML, Witteles RM, Fisher GA, et al: Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 19:1613-1618, 2008
66. Chu TF, Rupnick MA, Kerkela R, et al: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019, 2007 (Pubitemid 350236338)
67. Biolo A, Ramamurthy S, Connors LH, et al: Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: Relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ Heart Fail 1:249-257, 2008
68. Selvanayagam JB, Hawkins PN, Paul B, et al: Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 50:2101-2110, 2007 (Pubitemid 350117349)
69. Ewer MS, Lenihan DJ: Left ventricular ejection fraction and cardiotoxicity: Is our ear really to the ground? J Clin Oncol 26:1201-1203, 2008
70. Plana JC: Chemotherapy and the heart [in Spanish]. Rev Esp Cardiol 64:409-415, 2011
71. Geisberg CA, Sawyer DB: Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep 12:404-410, 2010
72. Sawaya H, Plana JC, Scherrer-Crosbie M: Newest echocardiographic techniques for the detection of cardiotoxicity and heart failure during chemotherapy. Heart Fail Clin 7:313-321, 2011
73. Sawaya H, Sebag IA, Plana JC, et al: Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107:1375-1380, 2011
74. Fallah-Rad N, Walker JR, Wassef A, et al: The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57:2263-2270, 2011
75. Walker J, Bhullar N, Fallah-Rad N, et al: Role of three-dimensional echocardiography in breast cancer: Comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 28:3429-3436, 2010
76. Cardinale D, Sandri MT: Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 53:121-129, 2010
77. Marenzi G, Giorgio M, Trinei M, et al: Circulating cytochrome c as potential biomarker of impaired reperfusion in ST-segment elevation acute myocardial infarction. Am J Cardiol 106:1443-1449, 2010
78. Montaigne D, Hurt C, Neviere R: Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies. Biochem Res Int 2012:951539, 2012
79. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513-10518, 2008
80. D'Alessandra Y, Devanna P, Limana F, et al: Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 31:2765-2773, 2010
81. Horie T, Ono K, Nishi H, et al: Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 87:656-664, 2010
82. Iguchi H, Kosaka N, Ochiya T: Secretory microRNAs as a versatile communication tool. Commun Integr Biol 3:478-481, 2010
83. Altena R, Perik PJ, van Veldhuisen DJ, et al: Cardiovascular toxicity caused by cancer treatment: Strategies for early detection. Lancet Oncol 10:391-399, 2009
84. Visscher H, Ross CJ, Rassekh SR, et al: Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 30:1422-1428, 2012
85. Deng S, Wojnowski L: Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 7:129-134, 2007 (Pubitemid 47339859)
86. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370-4378, 2007
87. Yeboah J, Folsom AR, Burke GL, et al: Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: The multi-ethnic study of atherosclerosis. Circulation 120:502-509, 2009
88. van Dalen EC, Caron HM, Dickinson HO, et al: Cardioprotective interventions for cancer patient receiving anthracyclines. Cochrane Database Syst Rev 6:CD003917, 2011
89. Kalay N, Basar E, Ozdogru I, et al: Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258-2262, 2006 (Pubitemid 44855419)
90. Nakamae H, Tsumura K, Terada Y, et al: Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104:2492-2498, 2005 (Pubitemid 41691573)
91. Bosch X, Esteve J, Sitges M, et al: Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: Rationale and design of the OVERCOME trial. J Card Fail 17:643-648, 2011
92. Pituskin E, Haykowsky M, Mackey JR, et al: Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): A randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 11:318, 2011